title: [Significance of Procalcitonin Measurement in Cases with Febrile Condition during Chemotherapy for Urological Cancer].
abstract: We examined the usefulness of measurement of procalcitonin (PCT) for patients, who developed febrile neutropenia during cancer chemotherapy for urological cancer. Of the Patients who underwent cancer chemotherapy for bladder, renal pelvic or ureteral, and testicular cancer in our department from 2010 to 2013, 51 had febrile events. Their clinical courses and PCT values were retrospectively reviewed and analyzed. PCT was positive in 12 patients and negative in 39. The duration with febrile status was significantly longer in the PCT-positive group than in the PCT-negative group. There was no significant difference between the blood count values in each group, but C-reactive protein (CRP) was significantly higher in the PCT-positive group than in the PCT-negative group. There were no significant differences between the 2 groups in other tests with blood. There were 12 patients with febrile neutropenia (FN) but all were classified into low-risk by the MASCC scoring system. Four of these 12 patients were positive for PCT. Our results suggested that, in patients with a fever of 37.5°C or more during the course of cancer chemotherapy for urologic cancer, bacteremia possibly existed if the patient was positive for PCT. In addition, the duration of fever tended to be longer and the condition was more severe. When the patients with urological cancer undergo cancer chemotherapy manifest high-grade fever, PCT is promising and valuable as an indicator of the severity of infection.
authors.affiliation: The Department of Urology, Sapporo Medical University School of Medicine.
authors.forename: Yuichiro
authors.initials: Y
authors.lastname: Kurimura
authors.affiliation: The Department of Urology, Sapporo Medical University School of Medicine.
authors.forename: Satoshi
authors.initials: S
authors.lastname: Takahashi
authors.affiliation: The Department of Urology, Sapporo Medical University School of Medicine.
authors.forename: Yoshiki
authors.initials: Y
authors.lastname: Hiyama
authors.affiliation: The Department of Urology, Sapporo Medical University School of Medicine.
authors.forename: Teruhisa
authors.initials: T
authors.lastname: Uehara
authors.affiliation: The Department of Urology, Sapporo Medical University School of Medicine.
authors.forename: Koji
authors.initials: K
authors.lastname: Ichihara
authors.affiliation: The Department of Urology, Sapporo Medical University School of Medicine.
authors.forename: Jiro
authors.initials: J
authors.lastname: Hashimoto
authors.affiliation: The Department of Urology, Sapporo Medical University School of Medicine.
authors.forename: Naotaka
authors.initials: N
authors.lastname: Nishiyama
authors.affiliation: The Department of Urology, Sapporo Medical University School of Medicine.
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Kitamura
authors.affiliation: The Department of Urology, Sapporo Medical University School of Medicine.
authors.forename: Naoya
authors.initials: N
authors.lastname: Masumori
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D002116:Calcitonin / Q000097:blood*; D015740:Calcitonin Gene-Related Peptide; D005260:Female; D005334:Fever / Q000139:chemically induced*; D006801:Humans; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D011498:Protein Precursors / Q000097:blood*; D012189:Retrospective Studies; D014571:Urologic Neoplasms / Q000188:drug therapy*; D055815:Young Adult
chemical_list: D000970:Antineoplastic Agents; C000606589:CALCA protein, human; D011498:Protein Precursors; D002116:Calcitonin; D015740:Calcitonin Gene-Related Peptide